Lenvatinib added to pembrolizumab demonstrated promising activity in patients with squamous cell carcinoma of the head and neck in an ongoing open-label phase Ib/II clinical trial.
The highly-selective RET inhibitor LOXO-292 demonstrated robust clinical activity across RET-altered solid tumors, including in patients with brain metastases and the RET V804M gatekeeper mutation.
Women with head and neck cancer may be severely undertreated and have higher death rates compared with their male counterparts.
Patients who used mobile and sensor technology to track their symptoms demonstrated reduced severity of their symptoms compared with patients who received standard care.
The FDA has approved combination therapy with dabrafenib and trametinib for the treatment of patients with unresectable or metastatic BRAF V600E–positive anaplastic thyroid cancer.
Robert L. Ferris, MD, PhD, discusses the implications of the updated findings from the phase III CheckMate-141 trial in squamous cell carcinoma of the head and neck.
Treatment with nivolumab reduced the risk of death by 32% compared with investigator’s choice of therapy for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
BLU-667, a next-generation tyrosine kinase inhibitor, appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prior therapies.
When investigators looked at roughly 150,000 cases of well-differentiated thyroid cancer using the SEER database of the National Cancer Institute, they knew that the use of radioactive iodine in conjunction with surgery and other treatments for thyroid cancer had increased dramatically over the years.
Nivolumab induced an overall response rate of 20.5% in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).